Engineering Functionally Improved CAR T cells with a Multi-Cytokine Backpack Platform with Insights into Metabolism

About this Webinar

Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieves a durable complete response (dCR). DCR has been correlated with CAR T cell products enriched with T cells of memory phenotypes. Therefore, reagents that consistently promote memory phenotypes during the manufacturing of CAR T cell products have the potential to significantly improve clinical outcomes. Researchers at Emory University, led by Dr. Sarwish Rafiq, have developed a novel modular multi-cytokine backpack (MCB) platform that combines the signals necessary for activation, co-stimulation, and cytokine support into a single “all-in-one” reagent for CAR T cell manufacturing.

Key Takeaways

• About a novel multi-cytokine backpack MCB activation, co-stimulation, ad cytokine support for effective CAR T cell product manufacturing
• A proof-of-principle of the powerful utility of the MCB platform to identify reagents that can improve the effectiveness of cell therapy products through optimal manufacturing
• Indications of differences in the metabolism of the MCB-manufactured T cells through spent media amino acid analysis